Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

22.26

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

0.22

EPS Last/This Y

-0.66

EPS This/Next Y

1.18

Price

1.22

Target Price

5.36

Analyst Recom

2.65

Performance Q

-64.64

Relative Volume

0.46

Beta

1.94

Ticker: EDIT



20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19EDIT1.330.100.3342249
2024-12-20EDIT1.320.090.0342587
2024-12-23EDIT1.260.090.5841554
2024-12-24EDIT1.20.090.5142050
2024-12-26EDIT1.2450.090.5342096
2024-12-27EDIT1.210.090.1942356
2024-12-30EDIT1.20.090.2143369
2024-12-31EDIT1.2750.090.2943743
2025-01-02EDIT1.310.090.1644100
2025-01-03EDIT1.330.090.0144515
2025-01-06EDIT1.440.090.0444390
2025-01-07EDIT1.4550.090.0745458
2025-01-08EDIT1.340.090.0845789
2025-01-09EDIT1.340.090.0745789
2025-01-10EDIT1.2650.090.0245821
2025-01-13EDIT1.1650.090.2046551
2025-01-14EDIT1.1350.090.0946734
2025-01-15EDIT1.220.080.1646366
2025-01-16EDIT1.250.080.1947412
2025-01-17EDIT1.220.080.1947467
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19EDIT1.33-71.3- -2.68
2024-12-20EDIT1.32-71.3- -2.68
2024-12-23EDIT1.25-54.8- -2.68
2024-12-24EDIT1.21-54.8- -2.68
2024-12-26EDIT1.23-54.8- -2.68
2024-12-27EDIT1.21-54.8- -2.68
2024-12-30EDIT1.20-54.8- -2.68
2024-12-31EDIT1.28-54.8- -2.68
2025-01-02EDIT1.31-54.8- -2.68
2025-01-03EDIT1.34-54.8- -2.68
2025-01-06EDIT1.43-54.8- -2.68
2025-01-07EDIT1.46-54.8- -2.68
2025-01-08EDIT1.34-54.8- -2.68
2025-01-09EDIT1.34-54.8- -2.68
2025-01-10EDIT1.26-54.8- -2.68
2025-01-13EDIT1.17-54.8- -2.68
2025-01-14EDIT1.13-54.8- -2.68
2025-01-15EDIT1.23-54.8- -2.68
2025-01-16EDIT1.25-54.8- -2.68
2025-01-17EDIT1.22-54.8- -2.68
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19EDIT-2.88-2.4419.64
2024-12-20EDIT-2.88-2.4419.64
2024-12-23EDIT-2.94-2.4019.64
2024-12-24EDIT-2.94-2.4019.64
2024-12-26EDIT-2.97-2.4020.70
2024-12-27EDIT-2.88-2.4020.70
2024-12-30EDIT-2.92-2.3720.70
2024-12-31EDIT-2.92-2.3720.70
2025-01-02EDIT-2.72-2.3720.70
2025-01-03EDIT-2.88-2.3720.70
2025-01-06EDIT-2.81-2.4120.70
2025-01-07EDIT-2.81-2.4120.70
2025-01-08EDIT-2.88-2.4120.70
2025-01-09EDIT-2.88-2.4120.70
2025-01-10EDIT-2.88-2.4120.70
2025-01-13EDIT-2.88-2.4022.26
2025-01-14EDIT-2.88-2.4022.26
2025-01-15EDIT-2.88-2.4022.26
2025-01-16EDIT-2.88-2.4022.26
2025-01-17EDIT-2.88-2.4022.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-0.75

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.53

Insider Transactions

-2.88

Institutional Transactions

-2.4

Beta

1.94

Average Sales Estimate Current Quarter

36

Average Sales Estimate Next Quarter

Fair Value

Quality Score

14

Growth Score

35

Sentiment Score

13

Actual DrawDown %

98.8

Max Drawdown 5-Year %

-98.7

Target Price

5.36

P/E

Forward P/E

PEG

P/S

1.63

P/B

0.57

P/Free Cash Flow

EPS

-2.56

Average EPS Est. Cur. Y​

-2.68

EPS Next Y. (Est.)

-1.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-340.96

Relative Volume

0.46

Return on Equity vs Sector %

-139

Return on Equity vs Industry %

-126.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

Editas Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 265
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
stock quote shares EDIT – Editas Medicine, Inc. Stock Price stock today
news today EDIT – Editas Medicine, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EDIT – Editas Medicine, Inc. yahoo finance google finance
stock history EDIT – Editas Medicine, Inc. invest stock market
stock prices EDIT premarket after hours
ticker EDIT fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About